Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia-Reference-Cited by-同舟云学术

Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia

Published:2020-05-11 Issue:6 Volume:20 Page:483-497
ISSN:1389-5575
Container-title:Mini-Reviews in Medicinal Chemistry
language:en
Short-container-title:MRMC

Author:

Hu Xu¹^ORCID,Wang Yan²^ORCID,Gao Xiang¹^ORCID,Xu Shengtao³^ORCID,Zang Linghe⁴^ORCID,Xiao Yan¹^ORCID,Li Zhanlin¹^ORCID,Hua Huiming¹^ORCID,Xu Jinyi³^ORCID,Li Dahong¹

Affiliation:

1. Key Laboratory of Structure-Based Drug Design &Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China

2. Valiant Co. Ltd., 11 Wuzhishan Road, YEDA Yantai, Shandong 264006, China

3. Department of Medicinal Chemistry and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China

4. School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China

Abstract

First stage human clinical trial (CTR20150246) for HAO472, the L-alanine-(14-oridonin) ester trifluoroacetate, was conducted by a Chinese company, Hengrui Medicine Co. Ltd, to develop a new treatment for acute myelogenous leukemia. Two patents, WO2015180549A1 and CN201410047904.X, covered the development of the I-type crystal, stability experiment, conversion rate research, bioavailability experiment, safety assessment, and solubility study. HAO472 hewed out new avenues to explore the therapeutic properties of oridonin derivatives and develop promising treatment of cancer originated from naturally derived drug candidates. Herein, we sought to overview recent progress of the synthetic, physiological, and pharmacological investigations of oridonin and its derivatives, aiming to disclose the therapeutic potentials and broaden the platform for the discovery of new anticancer drugs.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Liaoning Province

Department of Education of Liaoning Province

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology,General Medicine

Reference131 articles.

1. Greim H.; Kaden D.A.; Larson R.A.; Palermo C.M.; Rice J.M.; Ross D.; Snyder R.; The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci 2014,1310,7-31

2. Estey E.; Döhner H.; Acute myeloid leukaemia. Lancet 2006,368(9550),1894-1907

3. Bajaj J.; Konuma T.; Lytle N.K.; Kwon H.Y.; Ablack J.N.; Cantor J.M.; Rizzieri D.; Chuah C.; Oehler V.G.; Broome E.H.; Ball E.D.; van der Horst E.H.; Ginsberg M.H.; Reya T.; CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia. Cancer Cell 2016,30(5),792-805